Published in

American Association for Cancer Research, Cancer Research, 14(73), p. 4185-4189, 2013

DOI: 10.1158/0008-5472.can-13-0512

Links

Tools

Export citation

Search in Google Scholar

Exploiting Tumor Vulnerabilities: Epigenetics, Cancer Metabolism and the mTOR Pathway in the Era of Personalized Medicine

Journal article published in 2013 by Cristina Munoz-Pinedo ORCID, Eva Gonzalez-Suarez, Anna Portela, Antonio Gentilella, Manel Esteller
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Patient stratification according to drug responses, together with the discovery of novel antitumor targets, is leading to a new era of personalized cancer treatments. With the aim of identifying emerging pathways and the challenges faced by clinicians during clinical trials, the IDIBELL Cancer Conference on Personalized Cancer Medicine took place in Barcelona on December 3–4, 2012. This conference brought together speakers working in different areas of cancer research (epigenetics, metabolism and the mTOR pathway, cell death and the immune system, clinical oncology) to discuss the latest developments in personalized cancer medicine. Cancer Res; 73(14); 4185–9. ©2013 AACR.